---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016272"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:37:51.352689+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals subsidiary HOPE signs definitive agreement to acquire Kadima Neuropsychiatry Institute

## Summary
- Kadima is a profitable interventional psychiatry clinic in La Jolla, CA, expected to serve as clinical model for HOPE network.
- Dr. David Feifel, Kadima founder, to join HOPE as Chief Medical Innovation Officer upon closing.
- Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE.
- Closing subject to customary conditions and finalization of financing; further details to follow.
- Kadima is a leading investigative site for CNS and psychedelic research, including ketamine and TMS.

## SEC filing metadata
- accession: 0001437749-25-016272
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925016272/0001437749-25-016272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925016272/nrxp20250513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016272
- JSON: https://secwatch.observer/filing/0001437749-25-016272.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.